Table 1 JIA patients’ baseline characteristics
Characteristics | N = 36 patients | 95% CI |
|---|---|---|
Age (years), mean (SD) | 13.3 (3.1) | |
Females | 24 (66.7%) | 50.5–80.3 |
JIA subtype | ||
Oligo-articular JIA | 12 (33.3%) | 19.7–49.5 |
Poly-articular JIA | 10 (27.8%) | 15.3–43.7 |
Systemic JIA | 8 (22.2%) | 11.1–37.6 |
ERA | 5 (13.9%) | 5.5–27.8 |
Psoriatic arthritis | 1(2.8%) | 0.3–12.3 |
Disease duration (years), median (range) | 4.5 (0.3–11.0) | |
Medications | ||
NSAIDs | 5 (13.9%) | 5.5–27.8 |
Methotrexate | 15 (41.7%) | 26.7–57.9 |
Cyclosporine | 2 (5.6%) | 1.2–16.6 |
Adalimumab | 11 (30.6%) | 17.4–46.7 |
Etanercept | 7 (19.4%) | 9.1–34.4 |
Anakinra | 1 (2.8%) | 0.3–12.3 |
Tocilizumab | 4 (11.1%) | 3.9–24.3 |
Infliximab | 1 (2.8%) | 0.3–12.3 |
Off medications | 7 (19.4%) | 9.1–34.4 |
Associated comorbidity | 8 (22.2%) | 11.1–37.6 |
Obesity | 1 (2.8%) | 0.3–12.3 |
IDDM | 1 (2.8%) | 0.3–12.3 |
Hypothyroidism | 1 (2.8%) | 0.3–12.3 |
ADHD | 1 (2.8%) | 0.3–12.3 |
Short stature | 1 (2.8%) | 0.3–12.3 |
IBD | 1 (2.8%) | 0.3–12.3 |
Hyperlipidemia | 1 (2.8%) | 0.3–12.3 |
HIV | 1 (2.8%) | 0.3–12.3 |
Previous COVID-19 infection | 5 (13.9%) | 5.5–27.8 |
COVID-19 infection after vaccination | 3 (8.3%) | 2.4–20.6 |